Abstract: The present disclosure relates to a novel peptide derivative, etc., the peptide derivative being a partially modified adiponectin receptor peptide which, compared to conventional adiponectin receptor peptides, has higher stability, superior p-AMPK activity, and improved physical properties and activity and thus offers advantages when formulated into a drug. Therefore, the peptide derivative of the present invention can be used to prevent or treat inflammatory skin diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, to prevent or alleviate aging, sensitive skin, or wrinkles, or to enhance moisturization.

Abstract: The present invention relates to a novel peptoid derivative and the like. The peptoid derivative is obtained by partially modifying an adiponectin receptor peptide, and has high stability and excellent p-AMPK activity, compared to existing adiponectin receptor peptides and has improved physical properties and activity, thus having the advantage of being suitable for drug formulation. Therefore, the peptoid derivative of the present invention can be used for the prevention or treatment of skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, or the prevention or amelioration of aging, sensitive skin, wrinkles, or moisturization.

Abstract: The present disclosure relates to a 7-amino-3,4-dihydropyrimidopyrimidin-2-one derivative compound exhibiting excellent anti-proliferative effects against cancer cells, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a stereoisomer thereof, a production method therefor, a pharmaceutical composition for preventing, alleviating or treating cancer metastasis and proliferative disease containing the same as an active ingredient, and an anti-cancer composition against cancer cells. The compound exhibits excellent cancer cell inhibitory activity and anti-proliferative effects, and thus is effective in inhibiting cancer cells, preventing cancer metastasis and proliferative diseases or treating cancer.